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Dr David P. Bichell (Nashville, Tenn). Thank you for very
thought-provoking and well-presented data. Your group’s work
has helped frame the importance of hyperoxic injury from the
initiation of cardiopulmonary bypass, especially in cyanotic
infants, and now you very elegantly go further to show that the
injury is greatest for the single-ventricle cyanotic patients.
Other investigators have studied post-bypass hyperoxia-
induced stress injury and then have focused on pharmacologic
agents or other interventions to try to stamp out the fire already
lit by cardiopulmonary bypass and its inflammatory sequelae.
But your work points to a very appealing, practical, and more
preemptive approach of getting at the cause of it, and your
controlled reoxygenation strategy is appealing, especially
pertinent to the single-ventricle population, vulnerable in so
many ways and undergoing multiple insults on bypass, the
consequences of which compound.
I have a couple of questions.
The first is methodologic. In your 7-year follow-up data, the
single-ventricle patients, enrolled during the time of their Glenn
shunt, no doubt also underwent a Fontan procedure within the
study period. So that is 2 CPB runs. I just wonder how you treated
that with respect to the study design. In other words, if they were
randomized for hyperoxic versus controlled CPB at the first
operation, were those patients tracked and treated similarly at
the second insult of CPB? I am interested in how that fits in your
model and how that might affect the long-term data which, of
course, would then be influenced by multiple other factors.
Dr Caputo. If, for example, a patient undergoing a Glenn shunt
was randomized the first time, we could not recruit the same
patient for the total cavopulmonary connection. So when they
came to the Fontan, they were not randomized anymore. But we
did use the same strategy that was used for the first operation.
In a way, our study does really specifically consider the early
outcomes and biochemical markers of damage. Regarding the
follow-up, I do not think we have a significant number to have a
definite answer on the follow-up. So the outcomes of the follow-
up are more observational. We just wanted to present for the
completeness of the data, but we are not really saying that with
these numbers we randomized, we could have a definite answer
on the follow-up in terms of survival and ventricular function.800 The Journal of Thoracic and Cardiovascular SurgDr Bichell. It is an interesting striking difference in the
follow-up.
Dr Caputo. There is, yes.
Dr Bichell. It will be interesting to see more numbers for that.
Dr Caputo. Absolutely.
Dr Bichell. You divided your population into the single-
ventricle and biventricular patients, a heterogeneous mix of
each, and you nicely showed that a difference exists between the
2. Also, in the report, you speculated that the difference between
these 2 might be something to do with the chronicity and depth
of the cyanosis, with each respective group looking different,
and, therefore, the shock of hyperoxia looking different in 1 group
versus another.
But I wonder if there is not a more fundamental difference to
consider and perhaps consideration of dividing the groups
differently to be inclusive of the physiology that might drive
this. By that I mean, it is known that the lung is responsible for
an especially large portion of the reactivity of hyperoxic injury,
and it seems to me that the single-ventricle patients versus the
biventricular patients in general have parallel versus series
circulation. We are talking about an insult that occurs at the
initiation of CPB. In the parallel circulation patient, for example,
with shunt-dependent pulmonary blood flow, the initiation of
CPB results in distension of the pulmonary arterial tree with
hyperoxic blood, a shock, if you will, to the hypoxic initial state.
But for a septated, biventricular heart in series circulation, such
as a patient with tetralogy of Fallot, it is the opposite. The
pulmonary tree is actually emptied at the initiation of CPB.
Also, if there is hyperoxic injury, it is potentially more directed
to organs other than the lungs.
So I wonder if dividing the patients by series versus parallel
circulation, each group of which would contain some single and
some biventricular patients, you might further refine this effect
and/or explain it physiologically. That is a long way of asking,
have you considered this and were there patients in your study
who were, for example, a patient with tetralogy of Fallot with
major aortopulmonary collateral arteries who essentially had
systemic pulmonary circulation whose data can be analyzed to
see whether that is more of a physiologic explanation for the
difference you are seeing?
Dr Caputo. This is a really good suggestion. We have not
analyzed the data in that respect. Probably now that we have
finished the trial with>200 patients recruited, we should be able
to, because we might have enough numbers to subdivide into those
categories.
In this subgroup, some patients had a previous shunt and
possibly major aortopulmonary collateral arteries, but there were
not that many, so, again, to subdivide it into that group would
probably dilute the groups too much. But it is definitely something
that we should do with the larger cohort of patients.
In terms of why the single ventricle benefits more, several
explanations are possible. I think, as you suggested, there are
definitely patients with a double ventricle, such as, possibly, those
with transposition of the great arteries or very cyanotic tetralogy
with a Blalock-Taussig shunt, who could benefit as well. However,
perhaps, the ischemia reperfusion they undergo on top of the
oxygenation might have masked the effects of the benefits of the
oxygenation, because in single-ventricle patients, you either doery c September 2014
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Dnot crossclamp or the crossclamp time is very short. Thus,
probably the beneficial effect of controlling the reoxygenation is
not as evident in the biventricular repair where you do have to
crossclamp.
Dr Bichell.Well, this is very thought-provoking study and one
that I think can be integrated into a real practice change. I know I
had not before considered anything other than the dogmatic
approach of hyperoxic CPB, and you have given me pause to think
about this. I think this is an elegant method to connect data to a
change of practice.
Dr Caputo. Yes, thanks. Also, the good thing is that it is very
simple technique in a way, because it literally involves flushing
the CPB prime with nitric and it does not really affect the surgery,
the operation itself, so it is a quite simple technique.
DrMeena Nathan (Boston, MA).Are you planning to study the
neurologic outcomes of these patients? Do you have any early data
on that?
Dr Caputo. We just finished recruiting 230 patients, and we
followed them with Bayley’s and other neurocognitive tests for 6
months to 2 years, so I think the data will be available next
year, yes. That is our primary target, studying the neurologic
outcomes.
Dr Duke E. Cameron (Baltimore, Md). I enjoyed the study
very much as well. A quick question about your protocol. If I
read the slides right, on your controlled reoxygenation, you wereThe Journal of Thoracic and Cahypoxic at the institution of CPB but you allowed the oxygen
partial pressure to increase.
The reason I am asking this is that controlled reoxygenation
injury is worse in ischemic tissues than in those normally perfused,
and I am asking what was the oxygen partial pressure for these
patients just before the crossclamp was removed? Because I was
not clear of the rationale of lowering it when you institute CPB,
but letting it increase again and be hyperoxic just before
reperfusing the heart, which would be the organ most at risk of
this kind of injury.
Dr Caputo. That is a very good observation. We based our
strategy on our previous data. We analyzed the release of, for
example, troponin I in cyanotic patients, and it appeared that it
was the initial experience of the high oxygen during CPB that
created the damage. We saw as early as at 10 minutes of CPB,
an increase in the blood level of troponin I. So in the single
ventricle, most of these patients did not have the crossclamp, so
that was a very homogeneous group. That is why I think it was
the best possible group to study this entity. In the double ventricle,
I have not specifically concentrated on that. So, you are asking
what was the oxygen partial pressure when we crossclamp,
so before crossclamping?
Dr Cameron. Just before you came off.
Dr Caputo. We have not studied that. It is possibly a good
suggestion, and we should have the data to analyze.rdiovascular Surgery c Volume 148, Number 3 801
